- Adverum Biotechnologies Inc ADVM announced a restructuring plan, including reductions in headcount and expenses, to prioritize its clinical development of ADVM-022, a single intravitreal injection for wet age-related macular degeneration (AMD).
- Adverum intends these restructuring measures to fully support its ADVM-022 development plan, providing it with additional resources beyond one-year topline results from its Phase 2 LUNA trial.
- The company is reducing its workforce by 78 (approximately 38%).
- Adverum expects the workforce reduction to decrease its annual operating costs by approximately $15.3 million in direct labor costs.
- The company estimates to incur restructuring charges of approximately $4.2 million, to be recorded primarily in Q3 2022.
- The company is preparing to initiate the Phase 2 LUNA trial of ADVM-022.
- The LUNA trial will evaluate two doses in 72 patients with wet AMD.
- Truist Securities upgrades Adverum to Buy, with a price target raised to $4.
- Price Action: ADVM shares are up 4.70% at $1.28 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in